The PLATON Network
Megadott ok: Sponsor Decision
Key facts
- Where
- Bad Saarow, Berlin, Bochum, Chemnitz, Dortmund, Dresden, Essen, Frankfurt am Main, Goslar, Halle, Hamburg, Herne, Lahr, Landshut, Langen, Leer, Lemgo, Ludwigsburg, München, Münster, Neumünster, Ostfildern, Regensburg, Rheine, Saarbrücken, Singen, Witten és Wolfsburg, NémetországSee the 31 sites
Where in Németország
- HELIOS Klinikum Bad SaarowBad Saarow, NémetországNo longer taking part
- Evangelisches Waldkrankenhaus SpandauBerlin, NémetországNo longer taking part
- MVZ Oskar-Helene-Heim BerlinBerlin, NémetországNo longer taking part
- Augusta-Kranken-Anstalt BochumBochum, NémetországNo longer taking part
- Bochum UniBochum, NémetországNo longer taking part
- Klinikum ChemnitzChemnitz, NémetországNo longer taking part
- GEFOS - Gesellschaft für onkologische Studien DortmundDortmund, NémetországNo longer taking part
- Onkozentrum DresdenDresden, NémetországNo longer taking part
- Ev. Kliniken Essen-Mitte, Klinik für Internistische OnkologieEssen, NémetországNo longer taking part
- KHNW FrankfurtFrankfurt am Main, NémetországNo longer taking part
- MVZ Onkologische Kooperation HarzGoslar, NémetországNo longer taking part
- Universitätsklinikum Halle (Saale)Halle, NémetországNo longer taking part
- Hamburg Onkologische Schwerpunktpraxis EppendorfHamburg, NémetországNo longer taking part
- St. Anna Hospital HerneHerne, NémetországNo longer taking part
- Ortenau Klinikum Lahr-EttenheimLahr, NémetországNo longer taking part
- ÜBAG - MVZ Dr. Vehling-Kaiser GmbHLandshut, NémetországNo longer taking part
- Langen, Gemeinschaftspraxis für Hämatologie und OnkologieLangen, NémetországNo longer taking part
- Studienzentrum UnterEmsLeer, NémetországNo longer taking part
- Klinikum LippeLemgo, NémetországNo longer taking part
- Klinikum LudwigsburgLudwigsburg, NémetországNo longer taking part
- Klinik München-BogenhausenMünchen, NémetországNo longer taking part
- Münster, Gemeinschaftspraxis für Hämatologie und OnkologieMünster, NémetországNo longer taking part
- Friedrich-Ebert-Krankenhaus NeumünsterNeumünster, NémetországNo longer taking part
- Medius Klinik Osterfildern-RuitOstfildern, NémetországNo longer taking part
- Krankenhaus Barmherzige BrüderRegensburg, NémetországNo longer taking part
- Klinikum Rheine, Mathias-Spital RheineRheine, NémetországNo longer taking part
- CaritasKlinikum SaarbrückenSaarbrücken, NémetországNo longer taking part
- Onkologie BodenseeSingen, NémetországNo longer taking part
- Marien Hospital WittenWitten, NémetországNo longer taking part
- Klinikum WolfsburgWolfsburg, NémetországNo longer taking part
- Onkologisches Zentrum Wolfsburg-Helmstedt MVZ GmbHWolfsburg, NémetországNo longer taking part
Trial details
- Who runs it
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Trial code
- NCT05489250
- Record updated
- 2026. február 5.
- Original description
The PLATON Network study is designed to elevate personalized therapy based on genomic tumor profiles in gastrointestinal cancer patients. Hereby, PLATON's study-design focuses on the patient's tumor molecular profiling. Within the network a web application will be developed to link clinical investigators and information on study sites, cancer patients and genetic alteration data, as well as available clinical trials at PLATON's study sites.Read full original descriptionShow less
The Platform for Analyzing Targetable Tumor Mutations Network (Main-study)
The PLATON Network study is designed to elevate personalized therapy based on genomic tumor profiles in gastrointestinal cancer patients. Hereby, PLATON's study-design focuses on the patient's tumor molecular profiling. Within the network a web application will be developed to link clinical investigators and information on study sites, cancer patients and genetic alteration data, as well as available clinical trials at PLATON's study sites.
Inclusion: Histologically confirmed diagnosis of hepatocellular carcinoma or intra- cholangiocarcinoma, extrahepatic cholangiocarcinoma or gallbladder carcinoma or pancreatic ductal adenocarcinoma or esophagogastric adenocarcinoma in the advanced setting (adjuvant or neoadjuvant therapy is allowed if completed 6 months prior to enrolment) and no local curative therapy available; Standard first line therapy is planned, or patient is currently receiving first-line therapy; Available tumor-genomic profile ( ≥50-gene panel assay; approved and assessed by central review), unless central tumor genomic profiling is done within a sub-study; ECOG 0-2; Life expectancy ≥ 6 months.
Exclusion: Age < 18 years; Not able to understand all implications of study participation; No written informed consent.